-
SGI-1027 and Everolimus Disrupt Lysosomes in RCC
2026-09-29
The reference study shows that the DNMT1 inhibitor SGI-1027 cooperates with everolimus to suppress renal cancer through lysosomal membrane permeability, apoptosis, and GSDME-dependent pyroptosis. Its main contribution is a preclinical strategy for exploiting lysosomal vulnerability to address everolimus resistance while providing a framework for mechanistic live-cell analysis.
-
Topotecan and Dna2: Mapping Replication Stress
2026-09-29
Topotecan and SKF104864 provide a powerful way to interrogate topoisomerase I–linked replication stress. This article translates Dna2-mutant Drosophila findings into practical assay decisions for cancer research, with particular relevance to glioma and pediatric tumor models.
-
BRD4–RAC1 Co-targeting in Breast Cancer
2026-09-28
The reference study identifies combined BRD4 and RAC1 inhibition as a subtype-aware strategy that suppresses breast cancer growth, stemness, migration, and tumorigenesis. Its mechanistic contribution is the connection of BRD4–RAC1 blockade to the c-MYC/G9a/FTH1 axis and HDAC1-associated chromatin regulation, providing a framework for testing epigenetic dependencies alongside oncogenic signaling.
-
HCC sEV-CD147: Diagnostic Signal and Angiogenic Role
2026-09-28
Huang et al. report that CD147-positive small extracellular vesicles are more abundant in plasma from patients with hepatocellular carcinoma than in liver-cirrhosis and healthy comparison groups. Their functional experiments further link HCC-derived vesicular CD147 to endothelial angiogenesis, with PI3K/Akt activation and VEGFA upregulation implicated in the response.
-
Palomid 529 (P529) in ESCC Pathway Studies
2026-09-27
Use Palomid 529 (P529) to test whether mTORC1/2 signaling contributes to ESCC cell growth, cisplatin response, or angiogenic behavior—not as a direct inhibitor of the newly described RCN2–UBR5–PPP2CA axis. This guide turns the pathway findings into a controlled, dose-ranging workflow with practical assay choices and troubleshooting checkpoints.
-
Rapamycin in T-Cell Immunometabolism
2026-09-26
Rapamycin (Sirolimus) offers a direct way to perturb mTOR signaling, but its effects in immune assays depend on the cell population and functional endpoint. This article examines a study combining glycolysis inhibition with rapamycin to show how T-cell metabolism can change keratinocyte injury in oral lichen planus models.
-
In Vitro Protocols for Mammalian Embryonic Dormancy
2026-09-26
This Nature Protocols article describes noninvasive, in vitro methods for inducing and reversing a diapause-like dormant state in mouse blastocysts, human blastoids, and pluripotent stem cells through mTOR inhibition. The workflows make dormancy research more accessible and scalable while emphasizing that model-specific validation and careful assessment of reversibility remain essential.
-
Taltirelin Protects Dopaminergic Neurons in PD Models
2026-09-25
Zheng and colleagues found that Taltirelin reduced toxin-associated oxidative stress and cell death in neuronal models and improved motor performance while preserving nigral dopaminergic neurons in two mouse models of Parkinson’s disease. The study links these effects to lower MAO-B activity and reduced pathological tau and α-synuclein cleavage, providing a preclinical rationale for further testing rather than evidence of clinical disease modification.
-
mCherry mRNA as an Expression-Control Tool
2026-09-25
Learn how mCherry mRNA can help separate delivery and translation effects from biological reporter signals. This article connects the R1017 reporter to assay-design lessons from a bacterial NADH/NAD+ biosensor study—while clarifying where the two approaches differ.
-
Dihydroartemisinin: Translational Research Beyond the Label
2026-09-24
A translational framework for studying Dihydroartemisinin across malaria, mTOR signaling, and inflammation research—without confusing a compound’s reputation with evidence for a specific mechanism.
-
Bazedoxifene Workflows for ER and IL-6 Research
2026-09-24
Use Bazedoxifene to distinguish estrogen-receptor pharmacology from emerging IL-6/GP130 signaling effects in cell-based research. This practical guide combines setup choices, assay parameters, and troubleshooting while keeping osteoporosis models and exploratory cancer studies in their appropriate evidence contexts.
-
In Vitro mTOR Inhibition for Embryonic Dormancy
2026-09-23
This Nature Protocols article presents reproducible in vitro workflows for placing mouse and human early embryonic models into a reversible, diapause-like dormant state through pharmacological mTOR inhibition. Its main practical contribution is a noninvasive framework for comparing dormancy across blastocysts, blastoids, and pluripotent stem cells while defining readouts for state maintenance and reactivation.
-
AZD8055: Practical mTOR Inhibitor Workflow
2026-09-22
AZD8055 provides a selective ATP-competitive approach for investigating mTORC1 and mTORC2 signaling in biochemical, cellular, and animal research. It is best used for controlled mechanistic studies rather than clinical efficacy conclusions or experiments requiring a water-soluble compound.
-
Rapamycin (Sirolimus): mTOR Workflow Guide
2026-09-22
Build reproducible Rapamycin assays for mTOR signaling, proliferation, apoptosis, and immunosuppression research. This guide also translates emerging gut-microbiota findings into practical exposure, stability, and donor-resolved experimental workflows.
-
MLN4924: Reliable Neddylation Assay Design
2026-09-21
This scenario-driven guide explains how MLN4924 (SKU B1036) can help researchers connect NAE inhibition with cell-cycle, viability, and protein-degradation readouts. It covers mechanism, assay compatibility, stock preparation, interpretation, and practical supplier-selection criteria supported by product data and recent neddylation research.